RBC Capital Sees Eli Lilly’s (LLY) Retatrutide as Key Growth Driver despite Mixed Trial Results

Eli Lilly and Company (NYSE:LLY) is included among the 15 Dividend Stocks to Buy for Steady Income. RBC Capital Sees Eli Lilly’s (LLY) Retatrutide as Key Growth Driver despite Mixed Trial Results On March 19, RBC Capital said the overall tolerability and A1C reductions for Eli Lilly and Company (NYSE:LLY)’s retatrutide in the TRANSCEND-T2D-1 study came in worse than Mounjaro for type 2 diabetes patients. At the same time, weight loss and discontinuation rates leaned in favor of retatrutide. The analyst ...